Opportunity
Simpler Grants.gov #RFA-CA-27-016
NCI Seeks Lead Academic Organizations for Experimental Therapeutics Clinical Trials Network (ETCTN)
Buyer
National Institutes of Health
Posted
May 08, 2026
Respond By
June 30, 2026
Identifier
RFA-CA-27-016
NAICS
541715
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is seeking applications from institutions to serve as Lead Academic Organizations (LAOs) within the Experimental Therapeutics Clinical Trials Network (ETCTN). - Purpose: Establish or maintain LAOs to lead early phase clinical trials for new investigational drugs under NCI regulatory sponsorship - Responsibilities include: - Designing, developing, monitoring, conducting, and analyzing early phase clinical trials - Managing trials involving agents under Investigational New Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP) - Eligibility: - Academic centers and organizations in the US and Canada - Must provide direct medical care, have comprehensive medical training programs, investigational pharmacies, advanced imaging facilities, and preclinical laboratories - No specific OEMs, vendors, or commercial products are requested; this is a grant for clinical trial leadership and infrastructure - Total funding available: $11,800,000, with six expected awards - Notable requirements: - Applicants must demonstrate capacity for clinical research, regulatory compliance, and collaboration within a national network - Emphasis on infrastructure and expertise rather than procurement of equipment or software
Description
The National Cancer Institute (NCI) is soliciting applications from institutions to maintain or establish Lead Academic Organizations (LAOs) as part of the Experimental Therapeutics Clinical Trials Network (ETCTN). These LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials involving agents under regulatory sponsorship for New Investigational Drug applications held by NCI's Division of Cancer Treatment and Diagnosis. Each LAO will participate in clinical trials it leads as well as those led by other LAOs in the network. Eligible applicants include a range of government, nonprofit, educational, and business entities primarily in the US and Canada.